who inject drugs (PWID) are at high risk for serious but treatable and preventable medical consequences of their drug use, including HIV and Hepatitis C Virus (HCV) infections and fatal overdose. The current opioid crisis poses a threat for outbreaks of HIV among PWID, has resulted in increased incidence of HCV, and has led to dramatic increases in opioid overdose mortality. PWID need accessible medical treatment services for the consequences of their drug use. Syringe service programs (SSPs) are stigma-free settings that can provide PWID with healthcare services onsite or through close partnerships with local medical providers. In December 2015, the ban on Federal funding for SSPs was lifted. Since then the number of SSPs in the US has almost doubled, from 220 to approximately 430. Innovative models for delivering HIV and HCV care, HIV prevention (PrEP), and OUD medication at SSPs can expand PWID healthcare access, uptake and engagement, but they are not well described or evaluated systematically. Building on our previous studies of expanding HIV and HCV testing in substance use treatment programs, we propose to describe healthcare models that provide varying combinations of HIV, HCV, and opioid use disorder medication services onsite and off-site in the fast-growing SSP sector, and evaluate the feasibility of sustainably implementing them in different settings from the perspectives of the programs and their clients.
Our specific aims i n the next funding period include: 1) describing current models and recent trends of HIV and HCV care, PrEP, and OUD medication services in SSPs nationally; 2) assessing the feasibility of expanding SSP healthcare care models from SSP program perspectives; and 3) identifying drivers of preferences for different SSP healthcare models from SSP client perspectives. We will use a mixed-methods sequential approach by conducting two updated national SSP surveys to collect quantitative data and qualitative interviews with SSP program directors and staff in diverse settings, including SSPs that do and do not provide HIV, HCV, PrEP and OUD medication services onsite. Qualitative interviews will explore onsite versus off-site delivery options, costs, sustainability of services currently provided, and plans for future expansion in the context of local community needs and barriers. We will also conduct an innovative discrete choice experiment (DCE) survey with a geographically diverse sample of SSP clients to identify and quantify their relative preferences for attributes of HIV, HCV, PrEP and OUD medication services. Results will be disseminated to state and local policy makers, public health practitioners, and funding agencies. Simultaneously with completion of this research, we intend to contribute to and inform the development and initial testing of interventions that will assist SSPs in expanding HIV, HCV, PrEP and OUD medication services. Our findings about the feasibility of models and preferences for attributes will inform the implementation of services that will sustainably maximize uptake and engagement.

Public Health Relevance

People who inject drugs (PWID) are at high risk for serious but treatable and preventable medical consequences of their drug use, including HIV and Hepatitis C Virus (HCV) infections and fatal overdose. Syringe service programs (SSPs) are stigma-free settings that can provide PWID with healthcare services onsite or through close partnerships with local medical providers. Building on our previous studies of expanding HIV and HCV testing in substance use treatment programs, we propose to describe healthcare models that provide varying combinations of HIV, HCV, and opioid use disorder medication services onsite and off-site in the fast-growing SSP sector, and evaluate the feasibility of sustainably implementing them in different settings from the perspectives of the programs and their clients.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA027379-08
Application #
10005299
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Duffy, Sarah Q
Project Start
2009-09-01
Project End
2022-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Other Health Professions
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Traynor, Sharleen M; Rosen-Metsch, Lisa; Feaster, Daniel J (2018) Missed Opportunities for HIV Testing Among STD Clinic Patients. J Community Health 43:1128-1136
Schackman, Bruce R; Gutkind, Sarah; Morgan, Jake R et al. (2018) Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug Alcohol Depend 185:411-420
Behrends, Czarina N; Nugent, Ann V; Des Jarlais, Don C et al. (2018) Availability of HIV and HCV On-Site Testing and Treatment at Syringe Service Programs in the United States. J Acquir Immune Defic Syndr 79:e76-e78
Feaster, Daniel J; Parish, Carrigan L; Gooden, Lauren et al. (2016) Substance use and STI acquisition: Secondary analysis from the AWARE study. Drug Alcohol Depend 169:171-179
Perlman, David C; Jordan, Ashly E; Uuskula, Anneli et al. (2015) An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy 26:1056-63
Schackman, Bruce R; Leff, Jared A; Barter, Devra M et al. (2015) Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction 110:129-43
Linas, Benjamin P; Barter, Devra M; Morgan, Jake R et al. (2015) The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 162:619-29
Linas, Benjamin P; Barter, Devra M; Leff, Jared A et al. (2014) The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS 28:365-76
Linas, Benjamin P; Barter, Devra M; Leff, Jared A et al. (2014) The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One 9:e97317
Pho, Mai T; Linas, Benjamin P (2014) Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy. Hepatology 60:12-4

Showing the most recent 10 out of 16 publications